Skip to content
Evigrade
ModerateAtypical antipsychotic – dopamine and serotonin receptor antagonist×Acetyl- and butyrylcholinesterase inhibitor

Updated · Methodology

Mechanism

Cytochrome P450 enzymes play almost no part in rivastigmine metabolism. Cholinesterases themselves rapidly hydrolyse it, and the kidneys excrete its metabolites (Exelon SmPC, European Medicines Agency, EMA). In the liver, CYP2D6 and to a lesser extent CYP3A4 metabolise risperidone. The cholinesterase inhibitors donepezil and galantamine had no clinically relevant effect on risperidone pharmacokinetics (Risperdal SmPC). The risk of this combination is linked to effects on the heart. Rivastigmine can slow the heart rate, and bradycardia is a risk factor for torsade de pointes. QT prolongation can also occur with rivastigmine (Exelon SmPC, EMA). With risperidone, QT prolongation has been reported very rarely after marketing (Risperdal SmPC). Both drugs can also cause or worsen extrapyramidal symptoms (Exelon and Risperdal SmPCs).

Symptoms

The documents describe no symptoms specific to this combination. A slow heart rate can lead to fainting (Exelon SmPC, European Medicines Agency, EMA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Rivastigmine most often causes nausea and vomiting, especially during dose titration. In people with Parkinson's disease dementia, rivastigmine can worsen tremor and other extrapyramidal symptoms (Exelon SmPC, EMA). Risperidone can cause extrapyramidal symptoms, tardive dyskinesia and a fall in blood pressure on standing. People with Parkinson's disease or dementia with Lewy bodies are more sensitive to risperidone and may develop confusion, postural instability and frequent falls (Risperdal SmPC).

Management

No document contraindicates the combination. Use rivastigmine with caution together with drugs that prolong the QT interval or can cause torsade de pointes. Clinical monitoring with an electrocardiogram (ECG) may be needed (Exelon SmPC, European Medicines Agency, EMA). Use risperidone with caution together with drugs that prolong QT or cause bradycardia. This applies especially to people with heart disease, a family history of QT prolongation, bradycardia, or low potassium or magnesium (Risperdal SmPC). Rivastigmine can worsen extrapyramidal symptoms, so monitor for them (Exelon SmPC, EMA). If signs of tardive dyskinesia appear, consider stopping all antipsychotics (Risperdal SmPC). In older people with dementia, risperidone increases mortality and the risk of cerebrovascular events. Weigh the benefit and risk in them, taking stroke risk factors into account (Risperdal SmPC). The US Food and Drug Administration (FDA) has not approved risperidone for the treatment of dementia-related psychosis (Risperdal label, FDA). In Alzheimer's disease, risperidone is used only short term, up to 6 weeks, for persistent aggression in moderate to severe dementia, as an add-on to non-drug measures that have had limited or no effect, and when there is a risk of harm to the person or to others (Risperdal SmPC). People with other types of dementia should not receive risperidone (Risperdal SmPC). In Parkinson's disease, where rivastigmine is also used for dementia (Exelon SmPC, EMA), weigh the risks and benefits of risperidone because Parkinson's disease may worsen (Risperdal SmPC).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Risperidone

Other interactions with Rivastigmine